ASH 2020 Update: Anti-SARS-CoV-2 Antibody Response in Patients with Chronic Lymphocytic Leukemia
There has been concern about drug shortages during the COVID-19 pandemic. The CLL Society investigated these concerns and has been reassured that, at least for ibrutinib, there will be no impacts to the product supply.
Related posts